



May 26, 2017

Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 26, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic liver diseases, today announced that it will host a Key Opinion Leader call on the topic of Hepatic Encephalopathy and Other Complications of Liver Disease, on Friday June 2, 2017 at 11:00 am Eastern Time.

KOL Call: Hepatic Encephalopathy and Other Complications of Liver Disease

Date: Friday, June 2, 2017
Time: 11:00 am Eastern Time
From the US: 877-407-9716
International: 201-689-8453
Conference ID: 13663322
Webcast (with slides): <http://public.viavid.com/index.php?id=124676>

The call will feature a conversation with key opinion leader Robert S. Rahimi, MD, MSCR (Baylor Health Care System), who will discuss the unmet needs in hepatic encephalopathy (HE) and other complications of liver disease. Dr. Rahimi will be available to answer questions at the conclusion of the call.

Ocera Therapeutics' management will discuss the Company's ongoing clinical development of OCR-002 (ornithine phenylacetate). OCR-002 is in development in both an intravenous formulation which is well-suited for hospitalized population with overt HE, and an oral formulation for use as a step-down therapy and to provide a chronic use option to maintain remission of HE in patients with liver cirrhosis.

Robert Rahimi, MD, MSCR is board certified in Transplant Hepatology, Gastroenterology, and Internal Medicine, and a practicing physician at Baylor Health Care System. He currently treats patients with a variety of liver diseases, including chronic liver disease, liver cancer, liver failure, metabolic and autoimmune diseases of the liver, viral hepatitis, complications of cirrhosis, and liver transplantation. Dr. Rahimi has authored several research articles on improving the outcomes of patients with advanced liver disease. His research includes studying new treatments in development for Hepatitis, Liver Cancer, Cirrhosis, Liver Transplant, Acute Liver Failure, Chronic Liver Diseases, Hepatic Encephalopathy, and Metabolic Liver Diseases. Dr. Rahimi holds a Master of Science in Applied Physiology from Finch University of Health Sciences in North Chicago and medical degree from Chicago Medical School.

About Hepatic Encephalopathy

Hepatic encephalopathy is a debilitating and progressive complication of liver cirrhosis or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation, and in its more severe form, stupor, coma and even death.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.

Susan Sharpe
Ocera Therapeutics, Inc.
contact@ocerainc.com
919-328-1109